Celltrion has secured US Food and Drug Administration (FDA) approval to amend its Phase 3 clinical trial design for a proposed biosimilar referencing Merck’s blockbuster cancer immunotherapy Keytruda (pembrolizumab), according to company announcements. The strategic shift aims to accelerate development timelines for the biosimilar candidate, which targets a significant share of the global oncology market.
Celltrion Alters Phase 3 Trial Design
According to Celltrion, the regulatory green light allows the company to modify its ongoing global Phase 3 evaluation of the Keytruda biosimilar candidate, known experimentally as CT-P51. The adjustments focus on optimizing patient recruitment and trial endpoints to align with current regulatory standards set by United States health authorities. By streamlining the protocol, Celltrion intends to position the biosimilar competitively against the reference product as patents approach expiration.
The 44 Trillion Won Oncology Market
Keytruda remains one of the world’s top-selling pharmaceutical assets, generating massive annual revenues globally that approach or exceed multi-billion-dollar thresholds often cited near 44 trillion Korean won in cumulative market valuation terms. Merck’s PD-1 inhibitor is approved for dozens of indications, including non-small cell lung cancer, melanoma, and recurrent head and neck squamous cell carcinoma. Because of this broad clinical utility and high commercial return, pharmaceutical developers view Keytruda biosimilars as primary targets for future portfolio expansion.
Regulatory Pathway Forward
The FDA’s acceptance of the Phase 3 protocol amendment marks a practical step forward for Celltrion’s biosimilar pipeline, which already includes commercialized therapies for autoimmune diseases and oncology such as Remsima and Herzuma. Regulatory filings and clinical execution timelines will dictate when the company can formally submit a Biologics License Application (BLA) for review. Industry analysts note that successful execution of these revised trials will determine whether Celltrion can capture substantial market share once legal exclusivity protections surrounding Merck’s reference product lapse.
Related reading